Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

537 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico L, Menzel U, Prummer M, Müller P, Buchi M, Kashyap A, Haessler U, Yermanos A, Gébleux R, Briendl M, Hell T, Wolter FI, Beerli RR, Truxova I, Radek Š, Vlajnic T, Grawunder U, Reddy S, Zippelius A. D'Amico L, et al. Among authors: kashyap a. J Immunother Cancer. 2019 Jan 21;7(1):16. doi: 10.1186/s40425-018-0464-1. J Immunother Cancer. 2019. PMID: 30665463 Free PMC article.
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H. Trefny MP, et al. Among authors: kashyap as. Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14. Clin Cancer Res. 2019. PMID: 30765392
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS, Thelemann T, Klar R, Kallert SM, Festag J, Buchi M, Hinterwimmer L, Schell M, Michel S, Jaschinski F, Zippelius A. Kashyap AS, et al. J Immunother Cancer. 2019 Mar 12;7(1):67. doi: 10.1186/s40425-019-0545-9. J Immunother Cancer. 2019. PMID: 30871609 Free PMC article.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M, Ooi CH, Kreuzaler M, Hirschmann P, Guichard A, Rieder N, Bill R, Herting F, Kienast Y, Dirnhofer S, Klein C, Hoves S, Ries CH, Corse E, De Palma M, Zippelius A. Kashyap AS, et al. Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):541-551. doi: 10.1073/pnas.1902145116. Epub 2019 Dec 30. Proc Natl Acad Sci U S A. 2020. PMID: 31889004 Free PMC article.
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Trüb M, Uhlenbrock F, Claus C, Herzig P, Thelen M, Karanikas V, Bacac M, Amann M, Albrecht R, Ferrara-Koller C, Thommen D, Rothschield S, Savic Prince S, Mertz KD, Cathomas G, Rosenberg R, Heinzelmann-Schwarz V, Wiese M, Lardinois D, Umana P, Klein C, Laubli H, Kashyap AS, Zippelius A. Trüb M, et al. Among authors: kashyap as. J Immunother Cancer. 2020 Jul;8(2):e000238. doi: 10.1136/jitc-2019-000238. J Immunother Cancer. 2020. PMID: 32616554 Free PMC article.
Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.
Natoli M, Herzig P, Pishali Bejestani E, Buchi M, Ritschard R, Lloyd GK, Mohanlal R, Tonra JR, Huang L, Heinzelmann V, Trüb M, Zippelius A, Kashyap AS. Natoli M, et al. Among authors: kashyap as. Front Oncol. 2021 Mar 3;11:644608. doi: 10.3389/fonc.2021.644608. eCollection 2021. Front Oncol. 2021. PMID: 33747968 Free PMC article.
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity.
Kirchhammer N, Trefny MP, Natoli M, Brücher D, Smith SN, Werner F, Koch V, Schreiner D, Bartoszek E, Buchi M, Schmid M, Breu D, Hartmann KP, Zaytseva P, Thommen DS, Läubli H, Böttcher JP, Stanczak MA, Kashyap AS, Plückthun A, Zippelius A. Kirchhammer N, et al. Among authors: kashyap as. Sci Transl Med. 2022 Jul 13;14(653):eabm9043. doi: 10.1126/scitranslmed.abm9043. Epub 2022 Jul 13. Sci Transl Med. 2022. PMID: 35857639 Free article.
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, Everest-Dass AV, Wang J, Trefny MP, Monaco G, Bärenwaldt A, Gray MA, Petrone A, Kashyap AS, Glatz K, Kasenda B, Normington K, Broderick J, Peng L, Pearce OMT, Pearce EL, Bertozzi CR, Zippelius A, Läubli H. Stanczak MA, et al. Among authors: kashyap as. Sci Transl Med. 2022 Nov 2;14(669):eabj1270. doi: 10.1126/scitranslmed.abj1270. Epub 2022 Nov 2. Sci Transl Med. 2022. PMID: 36322632 Free PMC article.
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Fernandez-Rodriguez L, Cianciaruso C, Bill R, Trefny MP, Klar R, Kirchhammer N, Buchi M, Festag J, Michel S, Kohler RH, Jones E, Maaske A, Vom Berg J, Kobold S, Kashyap AS, Jaschinski F, Dixon KO, Pittet MJ, Zippelius A. Fernandez-Rodriguez L, et al. Among authors: kashyap as. J Immunother Cancer. 2023 May;11(5):e006714. doi: 10.1136/jitc-2023-006714. J Immunother Cancer. 2023. PMID: 37208130 Free PMC article.
537 results